European patent granted for POLB 001 in CRS

AI SummaryClose X

Poolbeg Pharma PLC has received formal notification from the European Patent Office of the decision to grant a European patent for its POLB 001 drug, which targets Cytokine Release Syndrome (CRS) in cancer immunotherapy. This significant milestone provides intellectual property protection in key European markets, strengthening the company's global patent portfolio and enhancing POLB 001's commercial value to potential partners as it advances through clinical trials, with interim data from the TOPICAL trial expected this summer.

Disclaimer*

UK 100

Latest directors dealings